Vical

Industry · 13 registered clinical trials.

Status	Trial	Phase	Started
Terminated	VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Invasive Aspergillosis, Invasive Pulmonary Aspergillosis	Phase 2	2018-02-20
Completed	Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine Herpes Genitalis	Phase 2	2016-09-01
Completed	Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults Genital Herpes Simplex Type 2	Phase 1 / Phase 2	2013-12-01
Completed	Pandemic Influenza Plasmid DNA Vaccines (Needle) Influenza	Phase 1	2007-08-01
Completed	Pandemic Influenza Plasmid DNA Vaccines (Needle-Free) Influenza	Phase 1	2007-08-01
Completed	A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage Metastatic Melanoma	Phase 3	2006-10-01
Completed	A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma Metastatic Melanoma	Phase 1	2005-07-01
Completed	Phase II Trial of Allovectin-7® for Metastatic Melanoma Melanoma, Metastatic Melanoma, Malignant Melanoma	Phase 2	2001-02-01
Terminated	Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer Prostate Cancer	Phase 1 / Phase 2	2000-11-01
Terminated	Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer Prostate Cancer	Phase 2	1999-06-01
Completed	Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma	Phase 2	1998-08-01
Completed	Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma	Phase 3	1998-07-01
Completed	Phase II Trial of Allovectin-7® for Head and Neck Cancer Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx, Head and Neck Neoplasms	Phase 3	—